As a model we chose to monitor the impact of Rbl2/p130 (L) mutations, which are recurrent co-mutations in SCLC patient tumors and accelerate SCLC tumorigenesis in mouse models [1, 15, 50]. Here, RBL2 is linked to small cell lung carcinoma.